Business, energy, technology, markets and global industry news from Business News Today

IMAAVY

PharmaDeviceNews IMAAVY
Pharma & Biotech

Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?

Discover what Johnson & Johnson’s new IMAAVY data mean for earlier gMG treatment, sustained control, safety and FcRn competition.

Read More
A hematology specialist reviews red blood cell findings as Johnson & Johnson advances nipocalimab as a potential first targeted treatment for warm autoimmune hemolytic anemia. Representative image.
Pharma & Biotech

Johnson & Johnson strengthens nipocalimab’s FDA case with rapid hemoglobin improvement

The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.

Read More
Representative image: A clinician reviews blood disorder data in a hospital setting, reflecting Johnson & Johnson’s IMAAVY Phase 2/3 results and the growing focus on FcRn-targeted treatment for warm autoimmune hemolytic anemia.
Pharma & Biotech

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.

Read More